Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 18/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.57 |
| ▸ | KIT | P10721 | 8/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.57 |
| ▸ | FLT3 | P36888 | 8/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840562 | 0.91 | CSF1R (0.55) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2845076 | 0.90 | CSF1R (0.57) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2842193 | 0.88 | CSF1R (0.59) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2845774 | 0.88 | CSF1R (0.62) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL14024768 | 0.87 | CSF1R (0.58) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2845036 | 0.87 | CSF1R (0.58) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2840605 | 0.87 | CSF1R (0.56) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2847207 | 0.86 | CSF1R (0.54) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2841953 | 0.86 | CSF1R (0.54) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2847678 | 0.86 | CSF1R (0.55) | CSF1RPDGFRBKITPDGFRAFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | claimed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | claimed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | CSF1R, CSF3R, FLT3 | CSF1R 1/4885PDGFRB 119/4885KIT 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.